Orforglipron vs Semaglutide
A non-peptide oral GLP-1 agonist against the injectable peptide standard.
The short answer: Orforglipron is a small molecule, not a peptide — which is why it survives the gut.
Orforglipron
Semaglutide
Compound in Ozempic® · Wegovy®Side by side
| Property | Orforglipron | Semaglutide |
|---|---|---|
| Research category | Metabolic Research | Metabolic Research |
| Presentation | 10mg oral tablets | 0.25mg × 4 pens |
| Dosage options | 10mg · 30mg | 0.25mg × 4 pens · 1mg × 4 pens · 2.4mg × 4 pens |
| Approved medicine using it | None — investigational | Ozempic® · Wegovy® |
| Availability | In stock | In stock |
| Batch COA | Supplied with order | Supplied with order |
| From | €227.90 | €292.90 |
How they differ
Semaglutide is a peptide, and peptides do not survive oral administration without help. Orforglipron is not a peptide at all: it is a small molecule that activates the GLP-1 receptor, designed from the ground up for oral use.
That distinction removes the absorption problem rather than working around it. Where oral semaglutide needs the SNAC enhancer and strict fasting conditions, orforglipron has no such constraints because it is absorbed like a conventional drug.
Handling differs accordingly. A small molecule is far more stable than a lyophilised peptide and is not subject to the same cold-chain and reconstitution requirements.
At the bench
A small molecule is far more stable than a lyophilised peptide: no cold chain, no reconstitution, no draw volume to calculate. That is the largest practical gap in this catalogue between two compounds acting on the same receptor.
What this comparison does not settle
Acting on the same receptor does not mean acting the same way. Small molecules and peptides can bind at different sites and produce different signalling profiles — an active area of the literature rather than a settled question.
Common questions
What is the difference between Orforglipron and Semaglutide?
Orforglipron is a small molecule, not a peptide — which is why it survives the gut. A non-peptide oral GLP-1 agonist against the injectable peptide standard.
Is Orforglipron or Semaglutide better?
Neither, and the question does not have a general answer. They are compared here on mechanism rather than merit. Acting on the same receptor does not mean acting the same way. Small molecules and peptides can bind at different sites and produce different signalling profiles — an active area of the literature rather than a settled question.
Which of the two has more published data?
Semaglutide. It is the compound behind Ozempic · Wegovy, so it carries a completed trial programme. Orforglipron remains investigational.
For research use only. Not for human consumption, diagnostic, therapeutic or veterinary use. Brand names are trademarks of their respective owners and are referenced only to identify the active compound — no affiliation or equivalence is claimed.